Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TVTX vs BHVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TVTX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

TVTX Overall Winner 6-Pillar Tally: TVTX 5 – 1 BHVN Matrix Metrics: TVTX 8 – 2 BHVN

As of Nov 16, 2026, Travere Therapeutics, Inc. (TVTX) is the stronger overall head-to-head candidate over Biohaven Ltd. (BHVN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TVTX carries a Unified Composite Score of 60.2/100 (BUY) at $50.05 (9.3x Forward P/E, -3.1% operating margin), whereas BHVN carries 42.1/100 (HOLD) at $13.95 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: TVTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TVTX vs BHVN
TVTX NASDAQ Head-to-Head Winner
Travere Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$50.05
-1.18% 1D
Market Cap $4.9B
TTM Revenue $651M
Forward P/E 9.3x
Beta / 30D Vol 1.39β · 44% Vol
Unified Composite Score
60.2 / 100 BUY
Tech 47.0 Fund 57.0 Flow 64.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.0%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $50.87 · SMA50: $55.62
BHVN NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.95
+0.9% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.40β · 111% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.9%) with fading momentum, RSI 48
RSI-14: 48.4 · SMA20: $14.55 · SMA50: $13.48

6-Pillar Scorecard Institutional Category Breakdown (TVTX 5 – 1 BHVN)

Columns: Metric · TVTX · BHVN
1. Valuation Multiples TVTX
Forward P/E 9.3x N/M
Trailing P/E 25.8x N/M
PEG Ratio N/M N/M
EV / Revenue 8.4x N/M
2. Growth & Scale TVTX
Revenue Growth (YoY) +36.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $651M N/A
Market Cap $4.9B $2.1B
3. Profitability & Quality BHVN
Gross Margin 61.1% N/A
Operating Margin -3.1% 0.0%
Net Profit Margin -18.7% 0.0%
Return on Equity (ROE) -321.2% -799.5%
4. Balance Sheet & Cash Flow TVTX
Cash Generation (TTM) -$27M -$473M
Cash Flow Margin -4.2% N/A
Net Cash / Leverage $493M Net Debt (27.28x D/E) $205M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TVTX
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 39.1% (6th %ile) 91.5% (18th %ile)
Put/Call OI Skew 0.05x (Call-Skewed) 0.31x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat TVTX
OpEx & R&D Intensity 64.2% of Rev ($418M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TVTX (8) vs BHVN (2)
Institutional Metric TVTX BHVN Criterion Row Edge
Market Capitalization
Scale
$4.9B $2.1B Larger Scale TVTX
Trailing P/E Ratio
Valuation
25.8x N/M Lower Multiple TVTX
Forward P/E Ratio
Valuation
9.3x N/M Lower Multiple TVTX
Revenue Growth (YoY)
Growth
+36.2% +0.0% Higher Growth TVTX
Operating Margin (TTM)
Profitability
-3.1% 0.0% Higher Margin BHVN
Net Profit Margin
Profitability
-18.7% 0.0% Higher Margin BHVN
Return on Equity (ROE)
Capital Efficiency
-321.2% -799.5% Higher ROE TVTX
52-Week Range Position
Momentum
60% ($23–$69) 59% ($8–$18) Stronger Trend TVTX
Beta / 30D Volatility
Risk Regime
1.39β · 44% Vol 1.40β · 111% Vol Lower Realized Risk TVTX
Unified Institutional Score
Composite Signal
60.2 / 100 (BUY) 42.1 / 100 (HOLD) Higher Composite TVTX
Trailing 12M Revenue (USD)
Operating Scale
$651M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$27M ($493M Net Debt (27.28x D/E)) -$473M ($205M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHVN +28.45 pp
TVTX: +0.91% · BHVN: +29.36%
3M Horizon BHVN +24.43 pp
TVTX: -21.67% · BHVN: +2.76%
6M Horizon BHVN +47.56 pp
TVTX: +16.69% · BHVN: +64.25%
1Y Horizon BHVN +24.91 pp
TVTX: +47.68% · BHVN: +72.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TVTX vs BHVN. Trailing 12-month operating profitability (TVTX -3.1% vs BHVN 0.0%) and valuation multiples (TVTX 9.3x vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TVTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$651M
Gross Margin61.1%
Op. Margin-3.1%
ROE / Fwd P/E-321.2% · 9.3x
BHVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-799.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TVTX CONSOLIDATION
101d in phase · OBV ACCUMULATION
Current IV 39.1%
IV Percentile 6th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact TVTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHVN CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 91.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BHVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TVTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.9B market capitalization and -3.1% operating margin.
OpEx & R&D Reinvestment 64.2% of Rev ($418M)
90D Engineering Disclosures 0 Published
BHVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TVTX vs BHVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Travere Therapeutics, Inc. (TVTX) is the stronger overall head-to-head candidate over Biohaven Ltd. (BHVN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TVTX carries a Unified Composite Score of 60.2/100 (BUY) at $50.05 (9.3x Forward P/E, -3.1% operating margin), whereas BHVN carries 42.1/100 (HOLD) at $13.95 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: TVTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TVTX leads the Growth & Scale pillar: TVTX posts +36.2% YoY revenue growth and +0.0% YoY earnings growth on $651M TTM revenue (61.1% gross margin, -3.1% operating margin), compared with BHVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TVTX generates $651M in USD-normalized revenue versus N/A for BHVN. In operating R&D and SG&A reinvestment, TVTX deploys 64.2% of Rev ($418M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BHVN.

TVTX screens cheaper on headline valuation multiples. TVTX trades at 9.3x Forward P/E, 25.8x Trailing P/E, N/M PEG, and 8.4x EV/Revenue (-4.2% FCF margin), whereas BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TVTX (-321.2% ROE) versus BHVN (-799.5% ROE) capital efficiency.

In options market volatility and institutional positioning, TVTX carries 39.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.39β · 44% Vol realized risk). By comparison, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.40β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.